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Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.021Recently, increasing attention has been directed toward
better understanding the physiological role and clinical
importance of a wide range of endogenously released vaso-
active peptides. The most well known of these are B-type
natriuretic peptide (BNP) and atrial natriuretic peptide
(ANP) (1–4). However, others have also attracted atten-
tion, including C-type natriuretic peptide, vasoactive intes-
tinal peptide, neuropeptide Y, the (uncertain in humans)
Dendroaspis-type peptide, and adrenomedullin (ADM)
(2–4). Although the sites of origin of these proteins differ
and the triggers for their release vary, they nonetheless
appear to play a role as endocrine/paracrine participants in
overall cardiovascular hemodynamic control (1). Further-
more, gene expression and release of these peptides are
affected by a wide range of disease states. In particular, the
clinical relevance of BNP, ANP, and ADM as markers of
disease severity has proved to be of special interest for
prognostic assessment of patients with chronic heart failure
or acute myocardial infarction (1,5–8).
See page 315
Human BNP, ANP, and ADM are well-known vascular
relaxation agents with diuretic properties (1–4,9,10). When
the relative concentrations of peptide release and chamber
weight are considered, BNP is predominantly of cardiac
ventricular origin and ANP is mainly of atrial origin. ADM,
on the other hand, has been identified in a wide range of
organ systems including the adrenal medulla (hence the
name), cardiac tissues, lungs, kidneys, and the gastrointes-
tinal system (9,10). Like BNP and ANP, ADM is a
vasodilator (acting through nitric oxide) and a natriuretic
agent that increases glomerular filtration. Also like BNP
and ANP, ADM production and release may be stimulated
by, among other things, physical stress, and vasoconstrictors
such as angiotensin II, norepinephrine, and endothelin-1.
ADM mRNA is induced in vascular smooth muscle and
cardiac cells by shear stress, stretch, hypoxia, and ischemia
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Medical School, Minneapolis, Minnesota. Both authors have reported that they have
no relationships relevant to the contents of this paper to disclose.(9–12). Presumably, like BNP and ANP, ADM’s principal
cardioprotective hemodynamic effect is a decrease in after-
load (reduction of peripheral resistance); however, it also
decreases preload by means of venous dilation and deters
adverse cardiac remodeling by reducing cardiac hypertrophy
and fibrosis.
Apart from their functional similarities, the manner in
which BNP, ANP, and ADM are released from tissues also
exhibit parallels. Each is released in the presence of cardiac
volume overload and stretch (1–4,11–13). BNP, ANP, and
ADM are each derived from larger precursor proteins and
cleaved at the cell surface to produce an active peptide and,
at least in the cases of BNP and ANP, a biologically inactive
or less active amino-terminal fragment (N-terminal BNP,
N-terminal ANP) (13). This processing step may be prob-
lematic in cardiac disease states such as heart failure. Recent
findings, particularly with regard to BNP, suggest that the
apparently increased BNP concentrations in heart failure
and acute ischemia may be contaminated by unprocessed
inactive/less active peptide (13,14). The result would be a
greater proportion of reduced-activity peptide being re-
leased, thereby undermining the pharmacological effective-
ness of the released hormone in terms of its cardioprotective
actions. If that is the case in diseased hearts, one might
predict that, were excess natriuretic peptide to be released,
for perhaps unknown reasons, in healthy individuals, the
released hormone would be composed of a complete com-
plement of fully active processed peptide. The result, even if
the excess peptide release were modest in amount, might be
a greater natriuresis and vasodilation than would otherwise
be expected; perhaps this is what occurs with ANP release
during episodes of paroxysmal supraventricular tachycardia
or atrial fibrillation (1–3,15).
Unlike BNP and, to a lesser extent, ANP the active form
of ADM is difficult to measure in plasma due to both its
short half-life and its tendency to bind nonspecifically to
various proteins. Given this constraint, it is now widely
accepted that measurement of the concentration of a more
stable midregional fragment (MR-proADM) is a suitable
surrogate for ADM concentration (7,8,12,16). The 2 pro-
teins are presumed to be produced in equimolar amounts,
and in previous studies, MR-proADM appeared to be a
promising biomarker for predicting prognosis in heart
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with ADM precursor processing (analogous to that ob-
served with BNP discussed earlier) remain to be addressed,
the use of MR-proADM as a surrogate for the active
peptide is likely acceptable in individuals without structural
cardiac disease such as is the case with most postural
orthostatic tachycardia syndrome (POTS) patients.
POTS remains a condition that has proved clinically very
challenging. Its onset is usually without evident explanation,
its pathophysiology is not adequately understood, its dura-
tion is entirely unpredictable, and there is no known
effective therapy (17–20). Consequently, efforts designed to
gain more sophisticated understanding of this mysterious
affliction are welcome. In this issue of the Journal, Zhang et
al. (21) investigated levels of circulating MR-proADM as a
surrogate for ADM in children carrying a diagnosis of
POTS. The authors report higher levels of MR-proADM
in otherwise healthy children with a clinical diagnosis of
POTS compared with normal controls. Further, they con-
cluded that MR-proADM 61.5 pg/ml provided a useful
cutoff to predict effectiveness of therapy with midodrine.
With regard to the latter, this same group previously
reported their experience suggesting that low-dose mido-
drine is beneficial in children with POTS, with success rates
approaching 70% in a presumably unselected (at least from
a vasoactive peptide consideration) population (22).
Inasmuch as ADM is widely dispersed in various tissues,
and particularly in vascular endothelium, Zhang et al. (21)
propose that ADM may be a contributor to the pathophys-
iology of POTS. This aspect of the study is interesting and
may open doors for further assessment of the role of
vasoactive peptides in this condition. On the other hand,
the observation that the POTS patients with the highest
ADM levels responded best to the vasoconstrictor prodrug
midodrine is more difficult to understand for several reasons.
First, although it is possible that the handling of midodrine
is different in Chinese children than in young persons in
Western countries, the vast extant reported experience in
the adolescent and young adult age groups does not tend to
indicate that midodrine at modest doses (even in combina-
tion with salt and volume for that matter) is predictably
effective for treating POTS. Second, in the current report by
Zhang et al. (21), reliance for success is placed on symptom
score improvement, whereas physiological measures such as
heart rate changes with upright posture (their Table 4) were
not substantially different between midodrine responders
and nonresponders ( heart rate post-treatment: 32.6 
4.8 beats/min vs. 32.2  10.4 beats/min, respectively)
espite the p values. Thus, it is difficult to ascribe any
enefit to cardiovascular physiological/pharmacological ef-
ects of midodrine. Third, the midodrine dose prescribed
as very low (2.5 mg/day) and does not seem to have been
dministered either in divided doses as its pharmacology
ould dictate (23), or based on weight, as is common
ractice in pediatrics. In this regard, midodrine is a prodrug
hat is well absorbed, but its effect is delivered after tonversion by hydrolytic cleavage to deglymidodrine. The
atter has a somewhat longer half-life than midodrine (2 to
h vs. 0.5 h) with a maximum effect at 1 h and a duration
f action of 4 to 6 h (23). Even allowing for some variability
that may be found in dysautonomia patients and potential
pharmacogenetic differences related to the Chinese patient
population, it is difficult to conceive that the pharmacolog-
ical effect could be long enough to be effective with
once-daily dosing. Finally, based on their midodrine obser-
vations, Zhang et al. (21) suggest that the high ADM
patients are the ones whose principal POTS pathophysiol-
ogy is vascular dilation (i.e., the redistributive form), as
opposed to the less common hyperadrenergic form, and thus
would be the subset best treated with vasoconstrictor agents.
This pathophysiological concept seems plausible. As noted
earlier, the natriuretic peptides including ADM are known
to be vascular relaxants and to reduce circulating volume by
several mechanisms, including fluid transfer through vessel
walls to the interstitium, diuresis, and redistribution, espe-
cially to the splanchnic bed (18,20). The latter is particularly
large potential circulating volume “sink,” which is known to
respond to nitric oxide in a manner that could fit one of the
ADM modes of action. In combination then, increased
ADM could account for the POTS clinical combination of
orthostatic intolerance and increased vascular permeability
with peripheral edema. Further, a net reduction of circulat-
ing volume may lead to decreased heart size and the need for
more rapid heart rates to accommodate to posture and
exercise (i.e., the tachycardia component of POTS) (24).
However, with all this having been said, one might have
expected that the utility of any therapeutic vasoconstrictor
agent would be more challenged, rather than less, in the
presence of high levels of ADM; in other words, one might
have predicted just the opposite effect than that reported in
this issue of the Journal by Zhang et al. (21).
Excluding concerns related to the role of midodrine in
POTS patients, the possibility that vasoactive peptides
contribute to the pathophysiology of POTS is intriguing.
As prime movers, such agents exhibit the pharmacological
effects that may explain many of the clinical findings in
POTS. However, the triggers (environmental, genetic,
some combination) that would cause such peptides to be
released in more than usual quantities are unknown. On the
other hand, the increased circulating presence of ADM (and
possibly other similar peptides) may simply be a secondary
response to other POTS-related issues. Thus, although
ADM does not appear to be much affected by exercise (25),
he rapid sinus rates in POTS patients may trigger peptide
elease analogous to the case of ANP in supraventricular
achycardias. Similarly, enhanced norepinephrine and/or
ndothelin release as part of a physiological adaptation to
aintain blood pressure during orthostatic stress could
rigger increased circulating ADM. Finally, although prob-
bly unlikely, a small heart size with vigorous contraction
ay play a role through increased shear stress on myocardialissues. With regard to the latter point, it has been suggested
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tionship with ADM concentrations (26).
In conclusion, the concept that vasoactive peptides may
contribute to the clinical manifestations of POTS is poten-
tially important. However, whether ADM and possibly
other peptides are active players or simply epiphenomena in
these patients will require considerable further study. At a
minimum, natriuretic peptide concentrations may prove to
be potentially useful markers of POTS severity that can be
tracked in individual patients as treatments are introduced
in an attempt to ameliorate the symptoms of this poorly
understood condition.
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